Ludovic Helfgott joined Novo Nordisk in April 2019 as Executive Vice President Rare Disease. Prior to joining Novo Nordisk, Ludovic worked for AstraZeneca from 2005 to 2018, most recently as Global Vice President in charge of the company’s Cardiovascular, Metabolism and Renal global franchise. From 1998 to 2005 he worked for McKinsey & Company.
Ludovic holds an MBA from INSEAD, MA in Finance & Strategy from the ESSEC business school, and MA with Major in Macro-Economics (Service Public) from the Institut d’études politiques de Paris.
Ludovic was elected as President of the Novo Nordisk Haemophilia Foundation Council in October 2020 after having served as Vice-President since May 2019.